IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) announced a proposed underwritten public offering of up to $300 million in common stock and pre-funded warrants. The company also plans to grant underwriters a 30-day option to buy up to $45 million of additional common shares.

The securities will be issued under an automatically effective shelf registration statement on Form S-3, with J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor as joint book-running managers.

Positive

• Proposed equity and warrant offering of up to $300 million
• Additional 30-day underwriter option for up to $45 million of common stock
• Use of an automatically effective Form S-3 shelf registration may streamline capital access

Negative

• New common shares and pre-funded warrants could increase the share count for existing IDYA holders
• Offering size, timing, and terms remain subject to market conditions and uncertainty

News Market Reaction – IDYA

-10.83% 3.4x vol

43 alerts

-10.83% Session close to close

+6.7% Peak Tracked

-5.9% Trough Tracked

$2.78B Market Cap

3.4x Rel. Volume

In the Jun 9 session, IDYA declined 10.83%, reflecting a significant negative market reaction. Argus tracked a peak move of +6.7% during that session. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.4x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.8% in the session following this news. A negative reaction despite the company...

Analysis

The stock dropped -10.8% in the session following this news. A negative reaction despite the company’s substantial cash balance of $972.9 million would have fit typical concerns around dilution. Prior offering headlines averaged a -1.93% move, so further downside would have remained broadly consistent with history. The existence of an active S-3ASR shelf and additional ATM capacity could have reinforced focus on future issuance as a risk to prior gains.

Key Figures

Proposed offering size: $300.0 million Underwriters’ option: $45.0 million ATM capacity: $350,000,000 +5 more

8 metrics

Proposed offering size $300.0 million Maximum common stock and pre-funded warrants in current underwritten offering

Underwriters’ option $45.0 million 30-day option for additional common stock in current deal

ATM capacity $350,000,000 Aggregate common stock sales allowed under ATM prospectus supplement

ATM remaining capacity $156.6 million Potential common stock sales under Open Market Sales Agreement with Jefferies

Cash & securities $972.9 million Balance as of March 31, 2026 per 10-Q

Current share price $28.29 Price before proposed June 8, 2026 offering announcement

52-week range $20.50–$39.28 Low and high over the past 52 weeks

Shares outstanding 87,856,154 shares Common stock outstanding as of March 31, 2026 per 424B5

Previous Offering Reports

3 past events · Latest: Jul 11 (Negative)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 11	Offering closing	Negative	+1.0%	Closed prior equity offering including full underwriter option exercise.
Jul 09	Offering pricing	Negative	-3.4%	Priced common stock and pre-funded warrants for public offering.
Jul 09	Offering proposed	Negative	-3.4%	Proposed public offering of common stock and pre-funded warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For prior offering-tagged events, IDYA’s average 24h move was -1.93%, with mostly modest negative reactions and one positive divergence.

Recent Company History

Recent IDYA history shows active use of the equity markets alongside clinical and corporate progress. In July 2024, the company announced and then closed a public offering of common stock and pre-funded warrants, with 24h moves around -3.37% on the proposal and +0.96% on closing. These financings followed growing pipeline investment and are consistent with the current proposed offering under an effective shelf framework.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, form s-3, +1 more

5 terms

pre-funded warrants financial

"offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"pre-funded warrants to purchase its common stock in an underwritten public offering."

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $45.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering.

The securities described above are being offered by IDEAYA pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by request from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities, by mail at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; UBS Investment Bank, by mail at UBS Securities LLC, 11 Madison Avenue, New York, NY 10010, Attention: Equity Syndicate, or by email at ol-prospectus-request@ubs.com; or Cantor, by mail at Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation statements regarding the offer and sale of securities, the terms of the offering and ability to complete the offering, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA's clinical programs, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials, enrollment rates, safety outcomes, efficacy results, regulatory interactions and decisions, and the ability to translate preclinical findings into clinical benefit, manufacturing and supply risks, competition, changes in standard of care, the timing and success of commercialization efforts, the outcome of collaborations and licensing arrangements, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect IDEAYA's ability to complete the offering. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA's filings with the SEC, including IDEAYA's most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the period ended March 31, 2026, any current and periodic reports filed with the SEC, and preliminary prospectus supplement related to the proposed public offering.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302794365.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What did IDEAYA Biosciences (Nasdaq: IDYA) announce on June 8, 2026?

IDEAYA Biosciences announced a proposed underwritten public offering of common stock and pre-funded warrants. According to IDEAYA, the proposed deal includes up to $300 million of securities, with a possible $45 million additional common stock via an underwriters’ 30-day option.

How large is the proposed IDEAYA (IDYA) stock and pre-funded warrant offering?

IDEAYA plans to offer up to $300 million of common stock and pre-funded warrants. According to IDEAYA, underwriters may also receive a 30-day option to buy up to $45 million of additional common stock, potentially bringing total gross proceeds higher if fully exercised.

What are the pre-funded warrants in IDEAYA’s June 2026 IDYA offering?

The company plans to offer pre-funded warrants as an alternative to common stock for certain investors. According to IDEAYA, these pre-funded warrants will be exercisable for common shares, alongside the direct sale of common stock in the underwritten public offering.

Who are the joint book-running managers for the IDEAYA (IDYA) June 2026 offering?

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are joint book-running managers. According to IDEAYA, these firms will manage the underwritten public offering of common stock and pre-funded warrants under the existing Form S-3 shelf registration.

How can investors obtain the IDEAYA (IDYA) June 2026 preliminary prospectus?

Investors can access the preliminary prospectus supplement via the SEC’s website when filed. According to IDEAYA, copies may also be requested from J.P. Morgan, Jefferies, TD Securities, UBS Investment Bank, or Cantor through their listed mail, phone, or email contacts.

What does the proposed IDEAYA (IDYA) equity offering mean for existing shareholders?

If completed, the offering could increase the number of IDEAYA shares outstanding. According to IDEAYA, it may sell up to $300 million in securities, with a 30-day $45 million underwriter option, which could affect ownership percentages.